DOYLESTOWN, PA, March 25, 2002 --The Quigley Corporation (NASDAQ: QGLY), the maker of Cold-Eeze®, the nation’s leading pharmacist-recommended cold remedy of its kind, today announced preliminary results of a retrospective clinical study confirming reduction in the use of antibiotics by patients who use Cold-Eeze as directed.
The independent retrospective study was conducted over a three year period and spanning more than 70,000 patient days on a student population ranging in age from 11 to 17 years. The findings proved that there was a dramatic statistical reduction in the use of antibiotic prescriptions for upper respiratory problems when Cold-Eeze was taken as directed.
Detailed results of the study will be submitted for publication in medical journals in the near future.
The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG™) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG™) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.